Ironwood Pharma Faces Delisting Notice
Ticker: IRWD · Form: 8-K · Filed: Mar 27, 2025 · CIK: 1446847
| Field | Detail |
|---|---|
| Company | Ironwood Pharmaceuticals Inc (IRWD) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Ironwood Pharma got a notice about possibly getting delisted. Big trouble.
AI Summary
Ironwood Pharmaceuticals, Inc. filed an 8-K on March 27, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer of listing. The filing also includes Regulation FD Disclosure and Financial Statements and Exhibits. The earliest event reported was on March 21, 2025.
Why It Matters
This filing indicates potential issues with Ironwood Pharmaceuticals' continued listing on an exchange, which could impact its stock value and trading accessibility.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock and operations.
Key Players & Entities
- IRONWOOD PHARMACEUTICALS, INC. (company) — Registrant
- March 21, 2025 (date) — Earliest event reported
- March 27, 2025 (date) — Date of report
- 100 Summer Street, Suite 2300 (address) — Principal executive offices
- Boston, Massachusetts (location) — Principal executive offices location
FAQ
What specific listing rule or standard has Ironwood Pharmaceuticals failed to satisfy?
The filing states a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not specify the exact rule or standard in the provided text.
What is the reason for the potential transfer of listing mentioned in the filing?
The filing indicates a 'Transfer of Listing' as an item of information, but the specific reasons for this transfer are not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on March 21, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at 100 Summer Street, Suite 2300, Boston, Massachusetts.
What type of SEC filing is this, and what other items are included?
This is a Form 8-K Current Report, which includes a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, and Financial Statements and Exhibits.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 27, 2025 regarding IRONWOOD PHARMACEUTICALS INC (IRWD).